Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Capio in conjunction with its acquisition of PR Vård
Mandate

Vinge advises Capio in conjunction with its acquisition of PR Vård

March 31, 2022 Employment and Benefits IT, Telecommunications and Outsourcing EU, Competition and Regulatory M&A Public Procurement

Vinge is advising Capio in connection with its acquisition of all shares in PR Vård Hemsjukvåd AB and PR Vård Mottagning AB.

PR Vård conducts home healthcare operations in five out of eight primary health areas in Stockholm as well as one surgery for children and young people and one healthcare surgery in Södermalm. PR Vård has 600 employees and performs approximately 1 million home healthcare visits per year. The acquisition is subject to approval by the Swedish Competition Authority.

Vinge’s team consisted of partner Anders Strid and Jenny Sandlund (project manager), Victoria Gunnerek (public procurement), Adam Löwenstein (tenancy law), Alexander Lindeberg (IT/GDPR), Anna Ståhlklo (employment law), Fredrik Löwenklou (M&A) as well as Anna Palmérus (competition law).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025